HOME >> BIOLOGY >> NEWS
Possible Trigger For Heart Failure Identified In Lab Animal Studies

DALLAS, April 14 -- Researchers have demonstrated in laboratory animals that tumor necrosis factor alpha, a protein produced in the heart, can lead to congestive heart failure. The finding may pave the way for a new treatment for the nation's fastest-growing heart disease. The studies, from two different research teams, appear in today's Circulation: Journal of the American Heart Association.

Released by the body to help heal injured tissue, tumor necrosis factor alpha (TNF), can initiate an "inflammatory cascade," or immune reaction, that may turn against the heart and weaken it, resulting in congestive heart failure, according to scientists at the University of Texas Southwestern Medical Center in Dallas and Baylor College of Medicine in Houston. One study also found that TNF is produced not just by white blood cells, but also by heart muscle cells called myocytes.

The Dallas scientists demonstrated that laboratory mice who were genetically altered so their heart cells produced an excess of TNF pumped less blood and developed an enlarged heart -- the primary features of congestive heart failure in humans.

Afflicting almost 5 million Americans, congestive heart failure is the single most frequent cause of hospitalizations for people age 65 or older, according to the American Heart Association. From 1979 to 1995, deaths from heart failure increased 115.7 percent.

In the study, researchers developed two lines of transgenic mice which expressed TNF in the heart. The two lines, which included 30 mice, died prematurely of heart failure. The progression of heart failure was directly related to the amount of TNF. Mice which did not express TNF in the heart proved to be free of disease, notes Deborah Bryant, B.S., the study's lead author. She is a senior research associate at U.T. Southwestern's department of pediatrics.

"Production of TNF by cardiac myocytes is sufficient to cause myocardit
'"/>

Contact: Carole Bullock
caroleb@amhrt.org
214-706-1279
American Heart Association
13-Apr-1998


Page: 1 2 3

Related biology news :

1. Possible new cure for psoriasis
2. Possible link discovered between gene responsible for blood vessel development and ACD in newborns
3. Possible mechanism for link between diabetes and Alzheimers disease discovered
4. Scientists switch components in cell circuits: Possible new technology, therapy
5. Possible new cell type found in developing inner ear
6. Possible gene for form of mental retardation, brain development identified
7. Possible cause and treatment for shock uncovered by UC San Diego bioengineers
8. Reproductive Signals Affect Lifespan In Roundworm C. Elegans, Offering Possible Insight Into Human Aging Process
9. UV Rays, Fire And Flame Retardants To Be Reviewed For Possible Listing As Carcinogens, NTP Announces
10. Coffee Without Addiction, Possible New Treatment For Osteoporosis, Wrinkle-Free Cotton, And More
11. Mechanism For Fungal Adherence Found, Possible Key To Disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Possible Trigger For Heart Failure Identified Lab Animal Studies

(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, ... devices with specialties in single use solutions, headquartered in ... MedConx, Inc. (a California corporation with ... San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing facility in ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
(Date:6/24/2015)... Biometry authentication provider KeyLemon today announced ... one face in. Logo - ... in, entering the expanding biometric authentication market in ... answer to the password problem. With advanced face ... KeyLemon, one face in allows users to securely ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
(Date:6/29/2015)... , ... June 29, 2015 , ... ... CAGR of around 19% during the forecast period (2015 to 2020). The market ... upsurge in government and corporate funding for R&D. However, lack of adequate healthcare ...
(Date:6/29/2015)... -- Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using ... cell therapy treatments for central nervous system diseases, announced ... the NASDAQ Capital Market under the symbol "CUR." The ... NYSE MKT until the market close on July 10, ... to commence on July 13, 2015. ...
(Date:6/29/2015)... June 29, 2015   For the seventh year running, ... assess their overall digital maturity called the Multichannel ... companies are not maturing fast enough. While it,s true ... numerous ways overall and customers are increasingly "digital natives", ... digital customer engagement.  ...
(Date:6/26/2015)... 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... all nominees listed in the management information circular ... 2015 Annual Meeting of Shareholders, held earlier today, ... the following 5 nominees proposed by management were ... until the Company,s next Annual Meeting of Shareholders ...
Breaking Biology Technology:Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3
Cached News: